Epi-Phare

Epi-Phare company information, Employees & Contact Information

Explore related pages

Related company profiles:

Le Groupement d’intérêt scientifique EPI-PHARE constitué fin 2018 par l’ANSM et la CNAM est une structure d’expertise publique indépendante en épidémiologie des produits de santé, autonome et réactive. EPI-PHARE réalise, pilote et coordonne des études de pharmaco-épidémiologie pour éclairer les pouvoirs publics dans leur prise de décision et répond à la demande croissante d’études basées sur les données complexes et massives du Système national des données de santé (SNDS).

Company Details

Employees
30
Founded
-
Address
143/147, Boulevard Anatole France, St.-Denis,ile-De-France 93200,france
Industry
Government Administration
NAICS
Public Administration
Justice, Public Order, and Safety Activities
Space Research and Technology
Legal Counsel and Prosecution
Correctional Institutions
Parole Offices and Probation Offices
Fire Protection
HQ
St.-Denis, Ile-de-France
Looking for a particular Epi-Phare employee's phone or email?

Epi-Phare Questions

News

Social and Regional Inequalities in Maternal Respiratory Syncytial Virus Vaccination in France - epi-phare

Social and Regional Inequalities in Maternal Respiratory Syncytial Virus Vaccination in France epi-phare

Real-world efficacy and safety of trastuzumab deruxtecan - epi-phare

Real-world efficacy and safety of trastuzumab deruxtecan epi-phare

Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants - epi-phare

Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants epi-phare

COVID-19 vaccination determinants in children aged 5–11 years - epi-phare

COVID-19 vaccination determinants in children aged 5–11 years epi-phare

Trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer - epi-phare

Trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer epi-phare

Use of Semaglutide (Wegovy) in Adults in France - epi-phare

Use of Semaglutide (Wegovy) in Adults in France epi-phare

Chlormadinone acetate and risk of intracranial meningioma - epi-phare

Chlormadinone acetate and risk of intracranial meningioma epi-phare

Award from the American Heart Association - epi-phare

Award from the American Heart Association epi-phare

Use of progestogens and the risk of intracranial meningioma - epi-phare

Use of progestogens and the risk of intracranial meningioma epi-phare

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines - epi-phare

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines epi-phare

Trastuzumab Deruxtecan in Metastatic Gastric Cancer - epi-phare

Trastuzumab Deruxtecan in Metastatic Gastric Cancer epi-phare

PrEP uptake among MSM in France - epi-phare

PrEP uptake among MSM in France epi-phare

Suivi de l’utilisation de Truvada® ou génériques - epi-phare

Suivi de l’utilisation de Truvada® ou génériques epi-phare

Risk of heavy menstrual bleeding following COVID-19 vaccination - epi-phare

Risk of heavy menstrual bleeding following COVID-19 vaccination epi-phare

Real-world effectiveness of HIV pre-exposure prophylaxis - epi-phare

Real-world effectiveness of HIV pre-exposure prophylaxis epi-phare

Roll-out of HIV pre-exposure prophylaxis use in France - epi-phare

Roll-out of HIV pre-exposure prophylaxis use in France epi-phare

mRNA Covid-19 vaccine dosing interval and the risk of myocarditis - epi-phare

mRNA Covid-19 vaccine dosing interval and the risk of myocarditis epi-phare

Medically Assisted Reproduction and Risk of Cancer Among Offspring - epi-phare

Medically Assisted Reproduction and Risk of Cancer Among Offspring epi-phare

Use of the French National Health Data System (SNDS) in pharmacoepidemiology - epi-phare

Use of the French National Health Data System (SNDS) in pharmacoepidemiology epi-phare

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe Covid-19 - epi-phare

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe Covid-19 epi-phare

COVID-19 Hospitalization in Solid Organ Transplant Recipients - epi-phare

COVID-19 Hospitalization in Solid Organ Transplant Recipients epi-phare

Antibiotic exposure during pregnancy - epi-phare

Antibiotic exposure during pregnancy epi-phare

Second-line biologics in psoriasis after first-line biologic failure - epi-phare

Second-line biologics in psoriasis after first-line biologic failure epi-phare

Use of mycophenolate - epi-phare

Use of mycophenolate epi-phare

Finasteride and suicidal risk - epi-phare

Finasteride and suicidal risk epi-phare

Hydroxychloroquine or chloroquine and risk of hospitalisation for Covid-19 - epi-phare

Hydroxychloroquine or chloroquine and risk of hospitalisation for Covid-19 epi-phare

Levonorgestrel Intrauterine Systems and Use of Psychotropic Drugs - epi-phare

Levonorgestrel Intrauterine Systems and Use of Psychotropic Drugs epi-phare

Antiepileptic drugs during pregnancy and neurodevelopmental outcomes - epi-phare

Antiepileptic drugs during pregnancy and neurodevelopmental outcomes epi-phare

A modified SCCS method with application to COVID-19 vaccine safety - epi-phare

A modified SCCS method with application to COVID-19 vaccine safety epi-phare

Proton Pump Inhibitors and Upper Gastrointestinal Bleeding - epi-phare

Proton Pump Inhibitors and Upper Gastrointestinal Bleeding epi-phare

Médicaments potentiellement inappropriés chez les personnes âgées - epi-phare

Médicaments potentiellement inappropriés chez les personnes âgées epi-phare

mRNA vaccine effectiveness against Covid-19 in elderly people - epi-phare

mRNA vaccine effectiveness against Covid-19 in elderly people epi-phare

New publication in Alimentary Pharmacologiy & Therapeutics - epi-phare

New publication in Alimentary Pharmacologiy & Therapeutics epi-phare

Prescribing Patterns of Codeine and Alternative Medicines in Children in Europe. - epi-phare

Prescribing Patterns of Codeine and Alternative Medicines in Children in Europe. epi-phare

Risk factors for Covid hospitalisation after booster vaccination during Omicron - epi-phare

Risk factors for Covid hospitalisation after booster vaccination during Omicron epi-phare

Drug use for gastrointestinal symptoms during pregnancy - epi-phare

Drug use for gastrointestinal symptoms during pregnancy epi-phare

Biologics and risk of serious infection in Patients with psoriasis - epi-phare

Biologics and risk of serious infection in Patients with psoriasis epi-phare

Interleukin 17 inhibitors: Risk of inflammatory bowel disease - epi-phare

Interleukin 17 inhibitors: Risk of inflammatory bowel disease epi-phare

Paclitaxel stents and balloons - epi-phare

Paclitaxel stents and balloons epi-phare

Vaccination obligatoire et épidémie de Covid-19 - epi-phare

Vaccination obligatoire et épidémie de Covid-19 epi-phare

Proton Pump Inhibitors and Risk of Pancreatic Cancer - epi-phare

Proton Pump Inhibitors and Risk of Pancreatic Cancer epi-phare

Grossesse et maladie inflammatoire de l’intestin - epi-phare

Grossesse et maladie inflammatoire de l’intestin epi-phare

Facteurs de risques d’hospitalisation et de décès à l’hôpital pour Covid-19 - epi-phare

Facteurs de risques d’hospitalisation et de décès à l’hôpital pour Covid-19 epi-phare

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis - epi-phare

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis epi-phare

Impact of Levothyrox formulation change on health and healthcare use in France - epi-phare

Impact of Levothyrox formulation change on health and healthcare use in France epi-phare

Médicaments des MICI et issues de grossesse - epi-phare

Médicaments des MICI et issues de grossesse epi-phare

Profiles of copper IUD and levonorgestrel intrauterine systems users - epi-phare

Profiles of copper IUD and levonorgestrel intrauterine systems users epi-phare

Utilisation intravitréenne d’anti-VEGF en France - epi-phare

Utilisation intravitréenne d’anti-VEGF en France epi-phare

Exposure to Mycophenolic Acid Products during pregnancy from 2010 to 2017 in France - epi-phare

Exposure to Mycophenolic Acid Products during pregnancy from 2010 to 2017 in France epi-phare

Anti-VEGF : risque d’infarctus du myocarde, d’AVC ou de décès - epi-phare

Anti-VEGF : risque d’infarctus du myocarde, d’AVC ou de décès epi-phare

Utilisation de Beyfortus® en ville lors de la première campagne de prévention - epi-phare

Utilisation de Beyfortus® en ville lors de la première campagne de prévention epi-phare

Utilisation prolongée de l’acétate de nomégestrol et risque de méningiome intracrânien - epi-phare

Utilisation prolongée de l’acétate de nomégestrol et risque de méningiome intracrânien epi-phare

Covid-19 : facteurs de risques hospitalisation décès - 2ème vague - epi-phare

Covid-19 : facteurs de risques hospitalisation décès - 2ème vague epi-phare

Acétate de cyprotérone : évaluation de l’impact des mesures de réduction du risque de méningiomes intracrâniens - epi-phare

Acétate de cyprotérone : évaluation de l’impact des mesures de réduction du risque de méningiomes intracrâniens epi-phare

Covid-19 et initatiation des traitements psoriasis - epi-phare

Covid-19 et initatiation des traitements psoriasis epi-phare

Chimiothérapie du cancer du sein et risque de cancers hématologiques secondaires - epi-phare

Chimiothérapie du cancer du sein et risque de cancers hématologiques secondaires epi-phare

PrEPP VIH : suivi de l’utilisation de Truvada® ou génériques - epi-phare

PrEPP VIH : suivi de l’utilisation de Truvada® ou génériques epi-phare

Top Epi-Phare Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant